世界の医療・医薬品産業レポート

TOP  >  作用機序別レポート  >  Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - パイプラインレビュー 2018年上半期

Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - パイプラインレビュー 2018年上半期
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Pipeline Review, H1 2018

レポートタイトル Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - パイプラインレビュー 2018年上半期
出版社名 Global Markets Direct
発刊日 2018-04-10
体裁 PDF / 99 ページ
シングルユーザ価格 US$ 3,500
レポート分類 作用機序別レポート
地域 グローバル
領域 -
疾患名 -
薬剤名 -
企業名 -
備考 ※ ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※ 本レポートは、英文です。PDF(電子媒体)での納品となります。

レポート概要

このレポートは、世界の主要国における上記の作用機序を標的とした治療薬パイプラインについての詳細な分析、該当作用機序についての包括的な情報、標的とする治療薬、および適応症、開発段階、作用機序(MoA)、投与方法(RoA)や分子タイプについての分析を提供します。
また、開発の歴史、最新のニュース、プレスリリースについても取り上げます。
さらに、開発中、開発中止プロジェクトの治療薬に関わる主要企業の概要も提供します。
また、該当作用機序の治療薬開発に関わる主要企業概要、開発中止プロジェクトの特集などを提供します。


Global Market Direct社のレポートは、20の治療領域および3000もの適応症をカバーした治験薬を特集しています。
本レポートは、Global Market Direct社独自のデータベース、企業/大学ウェブサイト、SEC書類、企業や大学のウェブサイトからのプレゼンテーションやプレスリリース、および業界特有の第三者情報源、自社分析を基にしたデータや情報を盛り込んでいます。


本レポートは、意思決定能力を高め、競争上の優位性を得るための効果的な戦略を立案するのに役立ちます。
ファーストインクラスやベストインクラス製品を作り出すため、新たなターゲットやMOAを特定することにより、R&Dパイプラインを強化します。


注)本レポートの一部のセクションは、該当疾患におけるデータの可用性や妥当性に基づいて、削除または変更される場合があります。

目次

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Overview
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Companies Involved in Therapeutics Development
Agenus Inc
Alligator Bioscience AB
Apogenix AG
Bicycle Therapeutics Ltd
BioInvent International AB
BioNTech AG
Bristol-Myers Squibb Co
Eli Lilly and Co
Juno Therapeutics Inc
KAHR medical Ltd
LeadArtis SL
MacroGenics Inc
Molecular Partners AG
Pfizer Inc
Pieris Pharmaceuticals Inc
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Drug Profiles
ABP-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Aptamer to Antagonize CD137 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATOR-1016 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATOR-1017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibody to Agonize CD137 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibody to Agonize CD40 and 4-1BB for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibody to Target EphA2 and CD137 for Solid Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target CD137L for Nasopharyngeal Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EU-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Agonize CD137 for Solid Tumor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISAS-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KAHR-105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KAHR-107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lisocabtagene maraleucel - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Agonize 41BB for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Target HER2 and CD137 for Solid Tumor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Agonize CD137 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Agonize TNFRSF9 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Target CD137 and IL2R for Metastatic Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MP-0310 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRS-342 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRS-343 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SCB-333 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Agonize CD137 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ultra-41BBL - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
urelumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
utomilumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Dormant Products
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Product Development Milestones
Featured News & Press Releases
Dec 12, 2017: Juno Therapeutics Highlights Data and Presentations Supporting Best-in-Class Strategy for JCAR017 at ASH
Dec 11, 2017: Juno Therapeutics and Celgene Corporation Release Additional Data from TRANSCEND Trial of JCAR017 in Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
Dec 09, 2017: Juno Therapeutics Highlights Key Translational Insights with JCAR017 in Patients with DLBCL
Nov 09, 2017: Molecular Partners Expands and Advances Robust Pipeline of DARPin Therapies in Oncology and Ophthalmology
Nov 01, 2017: Juno Therapeutics to Showcase Promising Data from JCAR-017 Product Development Program at ASH Conference
Oct 24, 2017: Alligator Bioscience Aptevo Therapeutics: Tumor antigen 5T4 associated with many forms of solid tumors identified as the second target for ALG.APV-527
Oct 24, 2017: Tumor Antigen 5T4 Associated With Many Forms of Solid Tumors Identified as the Second Target for ALG.APV-527 - a Novel Bispecific Antibody Candidate Being Developed by Alligator Bioscience and Aptevo Therapeutics
Oct 12, 2017: Pieris Pharmaceuticals Appoints Ingmar Bruns, M.D., Ph.D., as Vice President of Clinical Development
Oct 02, 2017: Pieris Pharmaceuticals Announces Dosing of First Patient in Phase I Trial for Fully Proprietary Lead IO Program, PRS-343
Aug 17, 2017: Aptevo Therapeutics and Alligator Bioscience Commence IND-Enabling Development Activities for New Bispecific Immunotherapy Candidate ALG.APV-527
Jun 17, 2017: Juno Therapeutics Presents TRANSCEND NHL 001 Trial Data at International Conference on Malignant Lymphoma
Jun 12, 2017: Alligator advances 4-1BB immuno-oncology antibody ATOR-1017 to pre-clinical development
Jun 05, 2017: Juno Therapeutics Presents Updated TRANSCEND NHL 001 Trial Data Demonstrating High Durable Response Rates in Patients with Relapsed or Refractory CD19+ Aggressive Non-Hodgkin Lymphoma
May 17, 2017: Juno Therapeutics to Present Key Clinical Data Updates on JCAR017 at the 2017 American Society of Clinical Oncology Annual Meeting
May 09, 2017: First-In-Human Clinical Trial Aims to Extend Remission for Children and Young Adults With Leukemia Treated With T-Cell Immunotherapy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Agenus Inc, H1 2018
Pipeline by Alligator Bioscience AB, H1 2018
Pipeline by Apogenix AG, H1 2018
Pipeline by Bicycle Therapeutics Ltd, H1 2018
Pipeline by BioInvent International AB, H1 2018
Pipeline by BioNTech AG, H1 2018
Pipeline by Bristol-Myers Squibb Co, H1 2018
Pipeline by Eli Lilly and Co, H1 2018
Pipeline by Juno Therapeutics Inc, H1 2018
Pipeline by KAHR medical Ltd, H1 2018
Pipeline by LeadArtis SL, H1 2018
Pipeline by MacroGenics Inc, H1 2018
Pipeline by Molecular Partners AG, H1 2018
Pipeline by Pfizer Inc, H1 2018
Pipeline by Pieris Pharmaceuticals Inc, H1 2018
Dormant Projects, H1 2018
Loading....